Pharmacological therapies for autism spectrum disorder: A review

P and T

Volumn 40, Issue 6, 2015, Pages 389-397

  LeClerc, Sheena ^a   Easley, Deidra ^b  

^a St Vincent's Hospital   (United States)

^b UNION UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; ATOMOXETINE; BACLOFEN; BUMETANIDE; CITALOPRAM; CLOZAPINE; DMXB A; FLUOXETINE; HALOPERIDOL; MELATONIN; MEMANTINE; METHYLPHENIDATE; MIRTAZAPINE; OXYTOCIN; RG 7314; RISPERIDONE; RIVASTIGMINE; SECRETIN; SERTRALINE; UNCLASSIFIED DRUG; VATIQUINONE; VENLAFAXINE;

AGGRESSION; ANTISOCIAL PERSONALITY DISORDER; ARTICLE; AUTISM; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMPULSION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INSOMNIA; IRRITABILITY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP; SPEECH DISORDER; STEREOTYPY; SYSTEMATIC REVIEW (TOPIC);

EID: 84930709229     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, Virginia: American Psychiatric Publishing, 2013
2. Autism Speaks. What is autism? 2015. Available at: http://www.autismspeaks.org/what-autism. Accessed February 6, 2015
3. Rice CE, Baio J, Van Naarden Braun K, et al. A public health collaboration for the surveillance of autism spectrum disorders. Paediatr Perinat Epidemiol 2007;21:179-190
4. Food and Drug Administration. FDA approves the first drug to treat irritability associated with autism, Risperdal. October 6, 2006. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm. Accessed January 27, 2015
5. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321
6. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44:1137-1144
7. Sharma A, Shaw S. Efficacy of risperidone in managing maladaptive behaviours for children with autistic spectrum disorder: a meta-analysis. J Pediatr Healthcare 2012;264:291-299
8. Bristol-Myers Squibb. U.S. Food and Drug Administration approves Abilify (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients (ages 6 to 17 years). November 20, 2009. Available at: http://news.bms.com/press-release/rd-news/us-food-and-drug-administration-approvesabilify-aripiprazole-treatment-irrita. Accessed January 28, 2015
9. Abilify (aripiprazole) prescribing information. Princeton, New Jersey: Bristol-Myers Squibb; December 2014. Available at: http://www.otsuka-us.com/Documents/Abilify.PI.pdf. Accessed January 28, 2015
10. Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. J Clin Psychiatry 2011;72:1270-1276
11. Varni JW, Handen BL, Corey-Lisle PK, et al. Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clin Ther 2012;34:980-992
12. Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012 May 16:5:CD009043. doi: 10.1002/14651858.CD009043.pub2
13. Clozaril (clozapine) prescribing information. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; December 2014. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf. Accessed January 28, 2015
14. Beherec L, Lambrey S, Quilici G, et al. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychopharmacol 2011;31:341-344
15. Posey DJ, McDougle CJ. Use of atypical antipsychotics in autism. In: Hollander E, ed. Autism Spectrum Disorders. New York, New York: Marcel Dekker, Inc.; 2003;247-264
16. Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliative Med July 2012. Available at: http://www.amepc.org/apm/article/view/1039/1266. Accessed January 28, 2015
17. Haldol (haloperidol) prescribing information. Raritan, New Jersey: Ortho-McNeil Pharmaceutical, Inc.; June 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018701s059lbl.pdf. Accessed January 27, 2015
18. MacDonald K, Wilson MP, Minassian A, et al. A retrospective analysis of intramuscular haloperidol and olanzapine in the treatment of agitation in drug-and alcohol-using patients. Gen Hosp Psychiatry 2010;32:443-445
19. Clinton JE, Sterner S, Stelmachers Z, et al. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 1987;16:319-322
20. Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry 1970;126:1670-1673
21. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989;28:87-92
22. Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a doubleblind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001;21:440-444
23. Zoloft (sertraline) prescribing information. New York, New York: Pfizer Inc.; May 2014. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=517 Accessed January 29, 2015
24. Bhardwaj A, Agarwal V, Sitholey P. Asperger’s disorder with co-morbid separation anxiety disorder: a case report. J Autism Dev Disord 2005;35:135-136
25. Hollander E, Soorya L, Chaplin W, et al. A double-blind placebocontrolled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry 2012;169:292-299
26. Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children with AD: a randomized, controlled, doubleblind trial. Eur Child Adolesc Psychiatry 2008;17:1-8
27. Gencer OF, Neslihan IE, Miral S, et al. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. Eur Child Adolesc Psychiatry 2008;17:217-225
28. Lee H-J, Macbeth AH, Pagani J, Scott WS. Oxytocin: the great facilitator of life. Prog Neurobiol 2009;88:127-151
29. Liu JCJ, McErlean RA, Dadds MR. Are we there yet? The clinical potential of intranasal oxytocin in psychiatry. Curr Psychiatry Rev 2012;8:37-48
30. Gordon I, Vander Wyka BC, Bennetta RH, et al. Oxytocin enhances brain function in children with autism. PNAS 2013;110:20953-20958
31. Preti A, Melis M, Siddi S, et al. Oxytocin and autism: A systematic review of randomized controlled trials. J Child and Adolesc Psychopharmacology 2014;24:54-68
32. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67:692-694
33. Kosaka H, Munesue T, Ishitobi M, et al. Long-term oxytocin administration improves social behaviors in a girl with autistic disorder. BMC Psychiatry 2012;12:110. doi: 10.1186/1471-244X-12-110
34. Chu JYS, Yung WH, Chow BKC. Secretin: a pleiotrophic hormone. Ann N.Y. Acad Sci 2006;1070:27-50
35. Agency for Healthcare Research and Quality. Therapies for children with autism spectrum disorders. Comparative effectiveness review no. 26. April 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/106/656/CER26_Autism_Report_04-14-2011.pdf. Accessed January 29, 2015
36. Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012 Apr 18;4:CD003495. doi: 10.1002/14651858.CD003495.pub3
37. Ritalin (methylphenidate) prescribing information. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; December 2013. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf. Accessed January 29, 2015
38. Concerta (extended-release methylphenidate) prescribing information. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; December 2013. Available at: http://www.janssenmd.com/pdf/concerta/CONCERTA_PI.pdf. Accessed January 29, 2015
39. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30:245-255
40. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007;61:538-544
41. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-1274
42. Effexor XR (extended-release venlafaxine hydrochloride) prescribing information. Philadelphia, Pennsylvania: Wyeth Pharmaceuticals Inc; December 2014. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=100. Accessed January 30, 2015
43. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:312-315
44. Prozac (fluoxetine) prescribing information. Indianapolis, Indiana: Eli Lilly and Company; July 2014. Available at: http://pi.lilly.com/us/prozac.pdf. Accessed January 30, 2015
45. Autism Speaks. Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA). February 18, 2009. Available at: http://www.autism-speaks.org/about-us/press-release/autism-speaks-announces-results-reported-study-fluoxetine-austism-sofia. Accessed January 30, 2015
46. Celexa (citalopram) proposed labeling text. St. Louis, Missouri: Forest Laboratories; January 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020822s037,021046s015lbl.pdf. Accessed January 30, 2015
47. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009;66:583-590
48. U.S. National Library of Medicine. Bumetanide-bumetanide injection: drug label information. December 2009. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a8f551b-9cdf-448d-94b1-df2291220aee. Accessed February 2, 2015
49. Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012;2:e202. doi: 10.1038/tp.2012.124
50. Namenda (memantine) prescribing information. St. Louis, Missouri: Forest Pharmaceuticals; October 2013. Available at: http://pi.actavis.com/data_stream.asp?product_group=1901&p=pi&language=E. Accessed February 2, 2015
51. Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16:517-524
52. Exelon (rivastigmine) prescribing information. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; October 2013. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf. Accessed February 3, 2015
53. Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004;19:165-169
54. Remeron (mirtazapine) prescribing information. Whitehouse Station, New Jersey: Merck & Comany, Inc.; September 2012. Available at: https://www.merck.com/product/usa/pi_circulars/r/remeron/remerontablets_pi.pdf. Accessed February 3, 2015
55. Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2011;11:267-277
56. Cortesi F, Giannotti F, Sebastiani T, et al. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012;21:700-709
57. Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: a sleep-promoting hormone. Sleep 1997;20:899-907
58. Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 2012;42:1729-1737
59. Roche. Product development portfolio. January 28, 2015. Available at: http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm. Accessed February 6, 2015
60. Autism Speaks. Strategic plan for science 2013-2017. January 25, 2013. Available at: http://www.autismspeaks.org/sites/default/files/docs/autism_speaks_strategic_plan_for_science:_2013-2017_final.pdf. Accessed February 6, 2015
61. National Institutes of Health, ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results?term=autism+spectrum+disorders&Search=Search. Accessed February 4, 2015
62. Campral (delayed-release acamprosate calcium) prescribing information. St. Louis, Missouri: Forest Pharmaceuticals, Inc.; January 2012. Available at: http://pi.actavis.com/data_stream.asp?product_group=1928&p=pi&language=E. Accessed February 6, 2015
63. Strattera (atomoxetine) prescribing information. Indianapolis, Indiana: Eli Lilly and Company; January 2015. Available at: http://pi.lilly.com/us/strattera-pi.pdf. Accessed February 6, 2015
64. Gablofen (baclofen injection) prescribing information. Hazelwood, Missouri: Mallinckrodt Brand Pharmaceuticals, Inc.; October 2013. Available at: http://www.mallinckrodt.com/gablofen/prescribinginfo. Accessed February 6, 2015
65. Kem W, Soti F, Wildeboer K, et al. The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): Chemical and pharmacological properties. Mar Drugs 2006;4:255-273
66. Edison Pharmaceuticals. Edison Pharmaceuticals announces initiation of EPI-743 Pearson syndrome clinical trial. March 17, 2014. Available at: http://edisonpharma.com/wp-content/files_mf/1395069300EdisonPearsonPressRelease_FINALMarch172014.pdf. Accessed February 6, 2015
67. Kumar B, Prakash A, Sewal RK, et al. Drug therapy in autism: a present and future perspective. Parmacol Rep 2012:64:1291-1304.